Neflamapimod's DLB Phase 3 hinges on landing a partner — post-hoc data rescues the science but not the balance sheet

CervoMed is a clinical-stage company developing a targeted neurological drug for dementia with Lewy bodies, a neurodegenerative disease, which is not yet approved.

CervoMed's neflamapimod failed its RewinD-LB primary endpoint in dementia with Lewy bodies, a fatal, treatment-void synucleinopathy, but post-hoc analyses attributing the miss to AD co-pathology contamination and one underexposed drug batch have kept regulatory agencies engaged, including FDA alignment on a registration path and UK ILAP designation. The thesis resolves on whether a strategic partner materializes to fund Phase 3, because $25M in cash covering only through Q3 2027 cannot self-fund a pivotal trial. The same exploratory subgroup data that rescued scientific credibility is the core regulatory risk: a Phase 3 built on post-hoc patient selection faces scrutiny over whether the enrichment strategy is pre-specified and adequately powered.